Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and a leading
cause of cancer-related deaths worldwide. Ninety percent of HCC cases arise from cirrhosis …

Hepatitis C virus (HCV) is an important human pathogen with a high chronicity rate. An
estimated 71 million people worldwide are living with chronic hepatitis C (CHC) infection …

Тенденция развития эпидемического процесса гепатита С в Узбекистане Page 431 431
ТЕНДЕНЦИЯ РАЗВИТИЯ ЭПИДЕМИЧЕСКОГО ПРОЦЕССА ГЕПАТИТА С В …

Discovery of hepatitis C in 1989 allowed basic research to identify critical components of
hepatitis C virus (HCV) structure and life cycle. Interferon (IFN)-α was introduced as first …

Background & Aims Direct-acting antiviral (DAA) therapy for HCV has high efficacy and
limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV …

Hepatitis C virus (HCV) infection develops into chronic hepatitis in over two-thirds of acute
infections. While current treatments with direct-acting antivirals (DAAs) achieve HCV …

The availability of safe, efficacious, oral direct-acting antivirals (DAAs) have ushered in a
new era of hepatitis C treatment with potential to eliminate hepatitis C as a public health …

Background Improved efforts in screening and treating chronic hepatitis C virus (HCV)
infection are expected to reduce its burden among adults on the liver transplantation (LT) …

Background With the introduction of direct-acting antivirals (DAAs) for hepatitis C virus
(HCV) infection, drug–drug interactions (DDIs) emerged as significant challenge. Since then …

More than five years ago, the treatment of hepatitis C virus infection was revolutionized with
the introduction of all-oral direct-acting antiviral (DAA) drugs. They proved highly efficient in …